孟鲁司特钠咀嚼片与吸入用布地奈德混悬液联合用于小儿哮喘治疗的疗效及不良反应观察

Efficacy and Adverse Reactions of Montelukast Sodium Chewable Tablets Combined with Inhaled Budesonide Suspension for the Treatment of Pediatric Asthma

目的探讨孟鲁司特钠咀嚼片结合吸入用布地奈德混悬液治疗小儿哮喘的效果.方法选择2021年3月—2023年5月枣庄市峄城区人民医院收治的88例哮喘患儿为研究对象,按随机数字表法将其分为对照组与观察组,各44例.对照组采用布地奈德混悬液治疗,观察组在对照组基础上联合孟鲁司特钠咀嚼片治疗.对比两组患者的临床疗效、炎症因子、肺功能指标、免疫功能及不良反应发生情况.结果观察组治疗总有效率为97.73%,高于对照组的79.55%,差异有统计学意义(P<0.05).治疗后,观察组白细胞介素-8、肿瘤坏死因子-α、白细胞介素-4水平均低于对照组,组间差异有统计学意义(P<0.05);观察组最大呼气流量、第1秒用力呼气容积、用力肺活量均大于对照组,组间差异有统计学意义(P<0.05);观察组免疫球蛋白G、免疫球蛋白A水平均高于对照组,组间差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论采用孟鲁司特钠咀嚼片联合吸入用布地奈德混悬液应用于哮喘患儿可减少炎症因子,对其肺功能、肝功能的改善效果显著,且不良反应少,有较好的安全性.

Objective To explore the effect of montelukast sodium chewable tablets combined with inhaled budesonide suspension in the treatment of pediatric asthma.Methods A total of 88 children with asthma treated in Yicheng District People's Hospital from March 2021 to May 2023 were selected as the study objects,and they were divided into a control group and an observation group according to random number table method,with 44 cases in each group.The control group was treated with Inhaled budesonide suspension,and the observation group was treated with Montelukast sodium chewable tablet based on the control group.The clinical efficacy,inflammatory factors,pulmonary function indexes,immune function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.73%,which was higher than 79.55%of the control group,the difference was statistically significant(P<0.05).After treatment,interleukin-8,tumor necrosis factor-αand interleukin-4 in observation group were lower than those in control group,and the differences were statistically significant(P<0.05);the maximum expiratory flow,forced expiratory volume in the first second and forced vital capacity in the observation group were higher than those in the control group,with statistical significance(P<0.05);immunoglobulin G and immunoglobulin A in the observation group were higher than those in the control group,and the differences between the two groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of montelukast sodium chewable tablets combined with inhaled budesonide suspension in children with asthma can reduce inflammatory factors,significantly improve lung and liver function,and have fewer adverse reactions,indicating good safety.